Table 1. Comprehensive list of known ALK fusion partners in NSCLC.
| ALK fusion partner (location) | Rearrangement type | Sensitive to crizotinib | Reference |
|---|---|---|---|
| EML4 (2p21) | Paracentric inversion | Yes | Soda et al. (2) |
| TFG (3q12.2) | Interchromosomal | Yes* | Horn et al. (3) |
| KIF5B (10p11.22) | Interchromosomal | Yes | Shaw et al. (4) |
| KLC1 (14q32.3) | Interchromosomal | Assumed | Shaw et al. (4) |
| STRN (2p22.2) | Complex rearrangement | Yes* | Majewski et al. (5) |
| HIP1 (7q11.23) | Interchromosomal | Yes* | Ou et al. (6) |
| PTPN3 (9q31) | Interchromosomal^ | N/A | Jung et al. (7) |
| TPR (1q25) | Interchromosomal | Assumed | Choi et al. (8) |
| BIRC6 (2p22.3) | Paracentric inversion | Yes | Ying et al. (In Press) |
| SOCS5 (2p21) | Complex rearrangement | Yes* | Drilon et al. (9) |
| CLIP4 (2p23.2) | Cryptic inversion** | Yes* | Drilon et al. (9) |
^, this is not a functional fusion; *, limited clinical experience, appears to be sensitive; **, due to genomic proximity (35 kb) of ALK and CLIP4, this is possible cryptic inversion. ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer.